Lexaria Bioscience Corp., a leader in drug delivery platform innovation, has announced the granting of two new international patents, elevating its global patent portfolio to 50. This achievement underscores the company’s commitment to broadening its intellectual property and enhancing its position in the pharmaceutical industry. The new patents include one in Australia for the treatment of epilepsy and another in Japan for the sublingual delivery of nicotine, both utilizing Lexaria’s proprietary DehydraTECH
technology.
The patent for epilepsy treatment expands Lexaria’s protection outside the USA, where it already holds six patents, and is set to expire in 2044. The nicotine delivery patent in Japan complements existing patents in the USA and Canada, with an expiration in 2043. These developments are significant given the epilepsy drug market’s projected growth to over $15 billion by 2032 and the global retail oral nicotine market’s expected annual growth rate of 26% until at least 2030.
Rich Christopher, CEO of Lexaria, highlighted the strategic importance of these patents in facilitating commercial deals within the pharmaceutical sector and building long-term value for stakeholders. The company’s DehydraTECH technology has demonstrated potential in increasing bio-absorption and improving drug delivery across the blood-brain barrier, offering promising avenues for treating epilepsy and enhancing nicotine absorption.
With the epilepsy market serving approximately 50 million people in the US alone and the nicotine pouch market anticipated to reach $25.4 billion by 2030, Lexaria’s latest patents position it at the forefront of addressing significant health and wellness challenges. The company’s achievement of 50 worldwide patents represents a decade-long vision coming to fruition, setting a solid foundation for future innovations and collaborations in the drug delivery space.
This news story relied on content distributed by None. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Lexaria Bioscience Corp. Achieves Global Patent Milestone with 50 Patents.